Unknown

Dataset Information

Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.


ABSTRACT: Gonadotropin-releasing hormone agonists (GnRHas) are standard of care for central precocious puberty (CPP). A 6-month subcutaneous injection has recently been approved by the Food and Drug Administration. Determine efficacy, pharmacokinetics, and safety of 6-month 45-mg subcutaneous leuprolide acetate for CPP. Phase 3 multicenter, open-label, single-arm study. 25 sites in 6 countries. 64 GnRHa-naïve children with CPP (age: 7.5 ± 0.1 years) received study drug: 59 completed the study. 2 doses of 45-mg subcutaneous leuprolide acetate (0.375 mL) at 0 and 24 weeks; children were followed for 48 weeks. Percentage of children with serum luteinizing hormone (LH) <4 IU/L 30 minutes following GnRHa stimulation at week 24. 54/62 (87%) children achieved poststimulation LH <4 IU/L at week 24; 49/56 (8

SUBMITTER: Klein KO 

PROVIDER: S-EPMC7442270 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature